Roche's emicizumab passes Phase III hemophilia A test

Roche (SIX:ROG; OTCQX:RHHBY) said emicizumab (ACE910) met the primary endpoint of the Phase III HAVEN 1 study as a prophylaxis for hemophilia A in patients with Factor VIII inhibitors. Compared with patients who received no prophylaxis, the therapy significantly reduced the number of bleeds over time.

Roche said emicizumab also met all of the study's secondary endpoints. The therapy significantly reduced bleeds over time in an intra-patient comparison in people who previously received bypassing agent prophylaxis treatment, and met other endpoints including quality of life assessments. The company plans to present data at a future medical meeting and submit them to regulators. Roche's Global Head of Hematology Development Nancy Valente declined to give a specific timeline to BioCentury...